TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01071174

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dapivirine
Description: Vaginal ring containing 25mg dapivirine; One ring inserted every 28 days for 84 days (3 rings total)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vaginal Ring containing no drug substance
Study: NCT03622762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: green tea extract
Description: Capsules of green tea extract, 400 mg twice a day, fasting

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules, 400 mg twice daily fasting
Study: NCT03795480

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOOD
Description: MOOD is an online self-help program targeted on depressive symptoms. The program consists of nine modules, one of which is an introductory module. The other modules are called: ABC-Scheme, Positive Activities, Self-Worth, Social Competence, Mindfulness, Modifying Thoughts, Sleep, and Relapse Prevention. All modules are based on principles of cognitive behavioral therapy (CBT) and include elements of mindfulness-based and metacognitive techniques. The modules contain interactive exercises which are aimed at incorporating the participant's experiences into the program and increasing identification of the participant with the presented material. Participants are free to work through the different modules in their own speed and way, however, it is recommended to work on one to two modules per week.
Study: NCT02510937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90001
Study: NCT03569501

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DHA
Description: 500 mg DHA tablets

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DHA
Description: 500 mg DHA tablets

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: oat grains
Description: 90 mg oat, containing 4.05 mg β-glucan

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oat grains
Description: 90 mg oat, containing 4.05 mg β-glucan
Study: NCT01126099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prazosin
Description: 4 mg capsules twice daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules twice daily for 12 weeks
Study: NCT02453464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevacizumab
Description: escalating doses of Sevacizumab : 3mg/kg，4mg/kg，5mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan: IV solution, IV over 90 minutes, 180 mg/m², Every 14 days, Until disease progression/toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 5-FU: IV solution, IV bolus over 2-4 minutes, 400 mg/m²; IV infusion over 46 hours, 2400 mg/m²; Every 14 days, Until disease progression/toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Leucovorin: IV solution, IV over 2 hours, 400 mg/m², Every 14 days, Until disease progression/toxicity
Study: NCT04531124

Intervention type: OTHER
Intervention: integrated management
Description: establish an integrated management on cardio-metabolic risk factors including hypertension by updating and upgrading the daily practice of practitioners and screening patients
Study: NCT00729521

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: facilitative system
Description: The facilitative system links communities with academic partners to provide communities with the skills and resources needed to help facilitate the community health improvement process. The system identifies what assets are available within communities, as well as the skills and resources needed to work through the community health improvement process. The facilitative system will then provide technical assistance, best practices guides, and direct consultation in carrying out all phases of the community health improvement process. This information is designed to increase community capacity in community assessment, coalition development, accessing and interpreting local injury prevention data, searching and selecting evidence-based research, and program planning and evaluation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Program
Description: a Standard Program group receiving modest funding to implement an evidence-based fall prevention program in their local community;
Study: NCT03221114

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Psychological Intervention
Description: Our culturally-tailored Positive Psychology Intervention is a non-pharmacotherapy approach aimed at increasing positive emotional experiences by teaching individuals to engage in intentional activities known to increase psychological and emotional well-being through targeting of constructs such as optimism, gratitude, mindfulness/relaxation, and resilience.
Study: NCT01116336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Participants will be given erlotinib orally (dose escalation from 50 mg, 75 mg, or 100 mg daily continuously for 6 cycles (each cycle is 28 days).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Green Tea Polyphenon E
Description: Participants will also be given PPE orally (200 mg EGCG) three times daily for 6 cycles (each cycle is 28 days). PPE capsules will be taken on a full stomach, within one hour after eating a substantial meal.
Study: NCT03695146

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Paced breathing
Description: Individuals will be fitted with a respiratory transducer and receive auditory tones with which to pace their rate of inspiration and expiration in the experimental group.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active relaxation
Description: Individuals will be provided with headphones while resting quietly listening to relaxing tones/music.
Study: NCT02626416

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LenZOC (mobile application)
Description: The transparency of the visual axial at the anterior segment is observed through a dilated pupil. Image of the eye of a patient taken with LenZOC is calibrated with a standardized white and black bar adhered to the patient's eyelid. Calibrated images are dimmed as graysalegrayscale. The intensity and progress of visual axial opacification (VAO) is quantified as absolute area and relative area (calculated as: absolute area of VAO/ absolute area of dilated pupil).
Study: NCT02850094

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Bonuses
Description: Each participant is eligible to receive $10 per week for increasing their minutes of moderate to vigorous physical activity by 10% from the previous week, or for meeting CDC guidelines of 150 minutes/week. Participants who meet their target minutes of PA every week for one month, three months, or six months receive $15, $25, or $50 bonuses respectively. If all members of a team meet their individual PA goals, each participant's reward is doubled. In total, participants can earn up to $860 if they meet all their goals.
Study: NCT00712452

Intervention type: OTHER
Group type: OTHER
Intervention: Biology and ultrasonography after chemotherapy
Description: Study of markers of ovarian reserve: Estradiol, LH, FSH and progesterone levels and ultrasonographic antral follicle count (no made in current practice)

Intervention type: OTHER
Group type: OTHER
Intervention: Biology and ultrasonography after chemotherapy
Description: Study of markers of ovarian reserve: Estradiol, LH, FSH and progesterone levels and ultrasonographic antral follicle count (no made in current practice)

Intervention type: OTHER
Group type: OTHER
Intervention: Biology and ultrasonography after chemotherapy
Description: Study of markers of ovarian reserve: Estradiol, LH, FSH and progesterone levels and ultrasonographic antral follicle count (no made in current practice)
Study: NCT01423825

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sub C gp140 Vaccine
Description: 100 mcg of Sub C gp140 vaccine admixed with MF59C.1 adjuvant administered as one 0.5 mL injection intramuscularly (IM) in either deltoid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59C.1 Adjuvant
Description: MF59C.1 adjuvant admixed with 100 mcg of Sub C gp140 vaccine administered as one 0.5 mL injection intramuscularly (IM) in either deltoid. MF59C.1 adjuvant contains no biologicals.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride
Description: Sodium chloride as 0.5 mL IM injection in either deltoid to act as placebo
Study: NCT03814564

Intervention type: DEVICE
Intervention: NIRS monitoring
Description: Cerebral and peripheral NIRS monitoring of brain and tissue oxygenation. Of the 400 patients, a subpopulation of the first 250 adult critically ill patients (≥18 years) requiring ICU care, including both surgical and medical ICU patients with circulatory shock will be included in the NIRS-substudy. All 400 patients will be analyzed for endotheliopathy incidence, metabolomics, genetic data Representation of the study population will be ensured by enrolment of all consecutive patients at the study sites who meet the study enrollment criteria
Study: NCT01190891

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Physical Therapy
Description: Same as arm description

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid Injection
Description: Dose represents a glucocorticoid potency of 400 hydrocortisone equivalents/injection (mg).
Study: NCT00044291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atamestane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: toremifene

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: letrozole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aromatase inhibition
Study: NCT03282669

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous hydromorphone
Description: Intravenous hydromorphone administered via IV in the post operative area.
Study: NCT01255631

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PEMF Device
Description: The PEMF device we will use in this study is FDA approved for adjunctive use in the palliative treatment of post-operative pain and edema in superficial soft tissue (510(k) number: K903675). There are no side effects to use of a PEMF device. In the treatment arm, the PEMF would be automatically delivered for 15 minutes every two hours for one month. The manufacturer (Ivivi Technologies, Inc., Northvale, NJ) has already designed a lightweight, disposable device that can be placed around the patient's arm and taped in place. The patient would keep the device in place for two weeks, when they return for a followup visit and receive a fresh device to wear for an additional two weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham PEMF Device
Description: Inactive PEMF device, delivers no PMF
Study: NCT02768532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: During each 8 visits (screening, V0, V1, V2, V3, V4, V5, V6) at weeks-1, 0, 2, 6, 10, 14, 22, 54, respectively), the following parameters will be systematically recorded: Crohn's disease Activity Index (CDAI), adverse events.~Blood and fecal samples will be systematically collected at weeks 0, 2, 6, 10, 14, 22 and 54 for routine serum ultrasensitive CRP (C-Reactive Protein) and fecal calprotectin assessments and for vedolizumab pharmacokinetic parameters, including the vedolizumab trough levels and the specific anti-Vedolizumab antibodies. In case of loss of response, an additional measurement of serum CRP (C-Reactive Protein), fecal calprotectin and Vedolizumab pharmacologic parameters will be performed.
Study: NCT00633646

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: diets contained different levels of protein
Description: diets contain protein in the range of 0.6-0.8 or 1.0-1.2 g/kg/d

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: diets contained different levels of protein
Description: diets contain protein in the range of 0.6-0.8 or 1.0-1.2 g/kg/d

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: diets contained different levels of protein
Description: diets contain protein in the range of 0.6-0.8 or 1.0-1.2 g/kg/d
Study: NCT00964275

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: diagnostic procedure
Description: Standard diagnostic procedures followed

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Description: PET with flueoxyglucose F 18
Study: NCT04164342

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: surveys
Description: Phone interviews to pass the Brief Pain Inventory (BPI) and the Patient Health Questionnaire-2 (PHQ-2) questionnaires (this is the intervention, since questionnaires at not usually done) at 3, 6 and 12 months after ICU discharge.
Study: NCT03363854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tralokinumab
Description: Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tralokinumab
Description: Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tralokinumab
Description: Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tralokinumab
Description: Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration.
Study: NCT00044291

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aromatase inhibition
Study: NCT03363854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo contains the same excipients in the same concentration only lacking tralokinumab.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo contains the same excipients in the same concentration only lacking tralokinumab.
Study: NCT01891942

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: twitch by magstim

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: twitch by magstim
Study: NCT03245853

Intervention type: DRUG
Group type: OTHER
Intervention: Riboflavin 5'-Phosphate
Description: Photrexa (riboflavin 5'-phosphate ophthalmic solution) 0.146%, is a yellow sterile buffered solution containing 1.46 mg/mL riboflavin 5'-phosphate, The pH of the solution is approximately 7.1 and the osmolarity is 157-177 mOsm/kg. Each 1 mL of the solution contains 1.53 mg of riboflavin 5'-phosphate sodium (equivilant to 1.20 mg \[0.12%\] riboflavin). Riboflavin 5'-phosphate sodium USP is a mixture of the sodium salts of riboflavin, riboflavin monophosphates, and riboflavin diphosphates. The inactive ingredients are dibasic sodium phosphate, monbasic sodium phosphate, sodium chloride, and water for injection.
Study: NCT02255253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan
Description: capsule,40mg per day,2 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Description: tablet, 25mg per day, 2 months
Study: NCT01787149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMARDs

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DMARDs
Study: NCT05882409

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Education covers women's education on violence, conflict and awareness.
Study: NCT02166996

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suture removal time 7 days
Description: To compare cosmetic outcome of surgical defects of head and neck, repaired with non-resorbable monofilament nylon sutures from the aspect of suture removal time 7 days.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suture removal time14 days
Description: To compare cosmetic outcome of surgical defects of head and neck, repaired with non-resorbable monofilament nylon sutures from the aspect of suture removal time 14 days
Study: NCT02081443

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor 180mg
Description: The proposed study will have a prospective, randomized, parallel design in which patients on chronic ticagrelor therapy will be assigned to receive a reloading dose of 90 or 180 mg ticagrelor. Platelet function assays will be done following in vitro incubation with and without 500 nM cangrelor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90mg
Description: The proposed study will have a prospective, randomized, parallel design in which patients on chronic ticagrelor therapy will be assigned to receive a reloading dose of 90 or 180 mg ticagrelor. Platelet function assays will be done following in vitro incubation with and without 500 nM cangrelor.
Study: NCT00449267

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraocular Lens
Description: Phacoemulsification with in the bag implantation of the IOL
Study: NCT02683772

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Astral
Description: Astral ventilator

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Astral
Description: Astral ventilator
Study: NCT04601675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab Ophthalmic and Intravitreal Dexamethasone
Description: Pro re nata patients with macula edema due to diabetes will receive Ranibizumab. Group A will continue to receive Ranibizumab depending on their clinical status of macular edema

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab Ophthalmic only
Description: Group B will initially receive intravitreal Dexamethasone and Ranibizumab and then depending on their clinical status of macular edema, Ranibizumab will be injected.
Study: NCT01640470

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Assistive Technology Provision and Tune-Up Intervention
Description: The home based AT Provision, Updating and Tune-Up (ATPUT) Intervention will consist of 5 components: 1) identification and prioritization of problematic activities by the assistance user and his/her principal, cohabitating caregiver; 2) in-residence assessment of the daily activities and social participation and preferences of the assistance user; 3) detailed review of the AT and human assistance that are currently being used; 4) recommendations by an occupational therapist for possible changes in the personal assistance strategy; 5) negotiation of an ATPUT Personal Plan with the assistance user and her/his principal caregiver.~The intervention occurs over a six week period and involves 3 to 6 visits from an occupational therapist.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Customary Care
Description: Participants in the customary care group receive normal occupational therapy services.Occupational Therapy
Study: NCT02735577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram
Description: Patients will be hospitalized on an inpatient psychiatric unit for 1-7 days to initiate abstinence. An fMRI scan will be performed to examine neural mechanisms of alcohol motivation. Prior to discharge, patients will receive the first dose of disulfiram 500 mg. They will then attend an outpatient clinic every other day for 14 days. At each clinic visit, they will receive 500 mg of disulfiram under supervision. Another fMRI scan examining alcohol motivation will be performed. Following this, all patients will attend the clinic weekly, and will be prescribed disulfiram 250 mg daily to take at home. This will be followed followed by an optional extension of weekly visits taking disulfiram 250 mg daily for another 28 days, for a total of 70 days of disulfiram treatment.
Study: NCT01695252

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MEMOS
Description: Patient informed clinical outcomes supervision
Study: NCT01332630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPI 287
Description: Starting dose Phase I: 160 mg/m2 by vein over 60 minutes on Days 1, 8, and 15 of every 28 day cycle.~Starting Dose Phase II: Maximum tolerated dose from Phase I.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 6 mg by mouth at 12 hours and 6 hours prior to treatment. As alternative and based on the treating physician discretion, dexamethasone 10 mg by vein may be given 30-60 minutes prior to treatment with TPI 287.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benadryl
Description: 12.5-25 mg intravenous (IV) push 30-60 minutes prior

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranitidine
Description: As H2 blocker 1mg/kg IV 30-60 minutes prior
Study: NCT03339583

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief behavioral therapy
Description: program included a question-and-answer part; a didactic presentation of sleep regulation mechanisms; the review of causes of onset and chronification of illness; an examination of patient's sleep log; explanation of sleep restriction method and prescription of individual regimen of sleep; explanation of stimulus control method; sleep hygiene education; discussion of relaxation techniques. Participants were supplied with 32 minute audio recording Relaxation and refreshment session for insomnia created for this study by Dr. A.Tabidze with verbal relaxing instructions with quiet musical composition behind it. Participants were instructed to listen to this recording in headphones each day for 2-week BBT-I period after laying into bed and turning the light off.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief behavioral therapy
Description: program included a question-and-answer part; a didactic presentation of sleep regulation mechanisms; the review of causes of onset and chronification of illness; an examination of patient's sleep log; explanation of sleep restriction method and prescription of individual regimen of sleep; explanation of stimulus control method; sleep hygiene education; discussion of relaxation techniques. Participants were supplied with 32 minute audio recording Relaxation and refreshment session for insomnia created for this study by Dr. A.Tabidze with verbal relaxing instructions with quiet musical composition behind it. Participants were instructed to listen to this recording in headphones each day for 2-week BBT-I period after laying into bed and turning the light off.
Study: NCT00044291

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hormone therapy